WallStreetZenWallStreetZen

NASDAQ: CYAD
Celyad Oncology Sa Stock

$0.83-0.05 (-5.68%)
Updated Mar 27, 2023
CYAD Price
$0.83
Fair Value Price
$1.48
Market Cap
$18.80M
52 Week Low
$0.46
52 Week High
$3.07
P/E
-0.43x
P/B
4.09x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$43.55M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
3.57
Operating Cash Flow
-$30M
Beta
0.81
Next Earnings
May 5, 2023
Ex-Dividend
N/A
Next Dividend
N/A

CYAD Overview

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CYAD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CYAD ($0.83) is undervalued by 43.71% relative to our estimate of its Fair Value price of $1.48 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CYAD ($0.83) is significantly undervalued by 43.71% relative to our estimate of its Fair Value price of $1.48 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CYAD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CYAD due diligence checks available for Premium users.

Be the first to know about important CYAD news, forecast changes, insider trades & much more!

CYAD News

Valuation

CYAD fair value

Fair Value of CYAD stock based on Discounted Cash Flow (DCF)
Price
$0.83
Fair Value
$1.48
Undervalued by
43.84%
CYAD ($0.83) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CYAD ($0.83) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CYAD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CYAD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.43x
Industry
18.55x
Market
21.44x

CYAD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.09x
Industry
4.86x
CYAD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CYAD's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CYAD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$21.0M
Liabilities
$16.4M
Debt to equity
3.57
CYAD's short-term assets ($15.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYAD's short-term assets ($15.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYAD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CYAD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
CYAD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CYAD vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CYAD$18.80M-5.24%-0.43x4.09x
CMRA$18.67M-5.53%-0.48x-2.99x
MTEM$19.05M+0.30%0.24x4.59x
SQZ$19.14M+7.45%-0.24x0.33x
ACST$19.23M+0.23%-1.27x0.20x

Celyad Oncology Sa Stock FAQ

What is Celyad Oncology Sa's quote symbol?

NASDAQ: CYAD) Celyad Oncology Sa trades on the NASDAQ under the ticker symbol CYAD. Celyad Oncology Sa stock quotes can also be displayed as NASDAQ: CYAD.

If you're new to stock investing, here's how to buy Celyad Oncology Sa stock.

What is the 52 week high and low for Celyad Oncology Sa (NASDAQ: CYAD)?

(NASDAQ: CYAD) Celyad Oncology Sa's 52-week high was $3.07, and its 52-week low was $0.46. It is currently -72.9% from its 52-week high and 80.87% from its 52-week low.

How much is Celyad Oncology Sa stock worth today?

(NASDAQ: CYAD) Celyad Oncology Sa currently has 22,593,956 outstanding shares. With Celyad Oncology Sa stock trading at $0.83 per share, the total value of Celyad Oncology Sa stock (market capitalization) is $18.80M.

Celyad Oncology Sa stock was originally listed at a price of $54.57 in Jun 19, 2015. If you had invested in Celyad Oncology Sa stock at $54.57, your return over the last 7 years would have been -98.48%, for an annualized return of -44.99% (not including any dividends or dividend reinvestments).

How much is Celyad Oncology Sa's stock price per share?

(NASDAQ: CYAD) Celyad Oncology Sa stock price per share is $0.83 today (as of Mar 27, 2023).

What is Celyad Oncology Sa's Market Cap?

(NASDAQ: CYAD) Celyad Oncology Sa's market cap is $18.80M, as of Mar 29, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Celyad Oncology Sa's market cap is calculated by multiplying CYAD's current stock price of $0.83 by CYAD's total outstanding shares of 22,593,956.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.